Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Structure and Function of Leukocytes01:21

Structure and Function of Leukocytes

5.0K
An adult in good health typically has between 4,500 and 11,000 leukocytes, or white blood cells, per microliter of blood, which constitutes about 1% of the total blood volume. Unlike red blood cells, white blood cells contain a nucleus and other cellular organelles but do not have hemoglobin. Most white blood cells reside in connective tissues, particularly in lymphatic organs such as the lymph nodes, with only a small fraction present in circulating blood.
White blood cells protect the body...
5.0K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.2K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introduction to the Review Series. Chronic myeloid leukemia in 2026.

Haematologica·2026
Same author

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

The New England journal of medicine·2026
Same author

Portrait of a Pioneer: Fred Appelbaum.

Transplantation and cellular therapy·2026
Same author

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

The New England journal of medicine·2026
Same author

Shared Identity and Patient Care: Adherence to Guideline-Recommended Biomarker Testing in Chronic Myeloid Leukemia.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Donor-derived del[20q] following allogeneic-hematopoietic cell transplantation: a case with 26-year follow-up and literature review.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Apr 24, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Structure, function, and resistance in chronic myeloid leukemia.

Jerald Radich1

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.

Cancer Cell
|September 10, 2014
PubMed
Summary
This summary is machine-generated.

Chronic myeloid leukemia (CML) treatment with tyrosine kinase inhibitors (TKIs) can fail due to compound mutations. These mutations alter protein structure, leading to TKI resistance and impacting patient outcomes.

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.1K

Related Experiment Videos

Last Updated: Apr 24, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

32.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chronic myeloid leukemia (CML) is a hematologic malignancy.
  • Tyrosine kinase inhibitors (TKIs) are standard therapy for CML.
  • TKI resistance can arise from complex genetic mutations.

Purpose of the Study:

  • To investigate the structural mechanisms underlying TKI resistance in CML.
  • To understand how compound mutations affect TKI sensitivity.

Main Methods:

  • Analysis of CML patient samples with compound mutations.
  • Structural biology techniques to examine protein changes.
  • Biochemical assays to assess TKI binding and inhibition.

Main Results:

  • Compound mutations induce significant structural alterations in the target kinase.
  • These structural changes impair TKI binding affinity.
  • Altered kinase conformation leads to reduced sensitivity to clinically relevant TKIs.

Conclusions:

  • Structural changes driven by compound mutations are a key mechanism of TKI resistance in CML.
  • Understanding these structural impacts is crucial for developing strategies to overcome resistance.
  • This research provides insights into the molecular basis of CML treatment failure.